BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ViaLogy Corp. Issued Key Patent For Biomarkers; Patent Further Strengthens Company's Proprietary Position


10/19/2005 5:09:37 PM

PASADENA, Calif.--(BUSINESS WIRE)--Jan. 6, 2004--ViaLogy Corp., inventor and developer of active signal processing software, today announced that it has been issued U.S. Patent No. 6,671,625 which describes use of its Quantum Resonance Interferometry (QRI) technology for detection and quantitation of biomolecular events above and below background noise. The patent extends QRI to protein arrays and broadens applications of QRI to proteomics, pathway optimization, high-throughput screening, cellular assays and time-based dosing studies by gene expression. ViaLogy already has been issued three U.S. Patents, numbers 6,245,511, 6,142,681 and 6,136,541 which describe the application of QRI technology to the analysis and interpretation of hybridized biochip and DNA microarray patterns including diagnostic applications.

"As demonstrated by our recently announced study with Zeptosens, our customers can now work with confidence at levels of sensitivity, specificity and reproducibility far below background noise and unattainable by other commercially available technology," said Doug Lane, ViaLogy's president and CEO. "This patent further strengthens ViaLogy's intellectual property position, especially for proteins, time-based measurements, and the discovery and monitoring of biomarkers."

Now available, ViaLogy® Microarray Analysis Service (VMAxS), is a highly focused application service for gene expression data, based on ViaLogy's QRI technology. Designed for large-scale users of microarrays such as major pharmaceutical, biotech and agricultural companies and institutional core laboratories, VMAxS reprocesses microarray raw data files from existing microarray instrumentation and databases and is available on a "pay-per-use" basis. The Company expects VMAxS to be available on-line and user-driven later this month for several microarray formats and will expand to other formats.

About ViaLogy Corp.

Founded in 1999, ViaLogy Corp., a privately held company located in Pasadena, California, develops and markets active signal processing software solutions for high technology industries. ViaLogy's founders were senior managers in super computing and quantum computing at Caltech/NASA Jet Propulsion Laboratory. ViaLogy discovered and developed a revolutionary technology, Quantum Resonance Interferometry (QRI), which is broadly scalable to a range of measurement instrumentation including microarrays, mass spectrometers, elemental analyzers, electron microscopes, wafer inspection systems, medical imaging, flow cytometers and high content screening. For more information please visit (www.vialogy.com).

(ViaLogy® is a US registered trademark of ViaLogy Corp.)

Contact:

ViaLogy Corp. Bud Bromley, 858-832-1099 bud.bromley@vialogy.com or Alchymia Communications for ViaLogy Corp. Doug Forsyth, 541-482-8744 df@alchymiacomm.com

Source: ViaLogy Corp.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES